Navirel (Vinorelbine)

Vinorelbine is a Vinca alkaloid used primarily in the treatment of certain solid tumors.

• Non‑small cell lung cancer: administered as part of combination chemotherapy to inhibit tumor growth.
• Metastatic breast cancer: used to control disease progression in patients who have received prior therapy.
• Other solid tumors: may be incorporated into regimens for advanced colorectal or ovarian cancers where standard options are limited.
• Pediatric solid tumors: evaluated in clinical studies for select sarcomas and neuroblastoma, though use is off‑label.
• Head and neck cancer: occasionally used in combination protocols for recurrent disease.

• Vinorelbine binds to the tubulin protein within microtubules, preventing their polymerisation and disrupting the formation of the mitotic spindle. This inhibition arrests cells in the M phase of the cell cycle, leading to apoptosis of rapidly dividing cancer cells. Its binding affinity is comparable to other Vinca alkaloids, contributing to its antimitotic potency.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: reduced neutrophil count leading to infection risk.
• Anemia: decreased red blood cells causing fatigue.
• Nausea: feeling of sickness often accompanied by vomiting.
• Vomiting: expulsion of stomach contents.
• Constipation: difficulty passing stools.
• Fatigue: generalized lack of energy.

Serious or Rare Side Effects

• Severe neutropenia with febrile infection: life‑threatening low white blood cells.
• Pulmonary toxicity: inflammation or fibrosis of lung tissue.
• Peripheral neuropathy: nerve damage causing tingling or pain.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: arrhythmias or reduced heart function.
• Hepatotoxicity: significant elevation of liver enzymes.

When using Navirel, clinicians should observe several precautionary measures to minimise risks.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate pulmonary status: screen for pre‑existing lung disease and monitor for respiratory symptoms.
• Use caution in cardiac disease: avoid in patients with significant arrhythmias or heart failure.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: agents such as ketoconazole may increase vinorelbine toxicity.
• Strong CYP3A4 inducers: drugs like rifampin can reduce therapeutic levels.
• Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Antiemetics containing CYP3A4 activity: may alter drug clearance and require dose adjustment.
• Live vaccines: immunosuppression from vinorelbine can increase risk of infection.